48,274 Shares in Cencora, Inc. $COR Acquired by Callan Family Office LLC

Callan Family Office LLC purchased a new stake in Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 48,274 shares of the company’s stock, valued at approximately $13,661,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of COR. C M Bidwell & Associates Ltd. purchased a new stake in Cencora during the second quarter worth approximately $212,000. Keating Financial Advisory Services Inc. purchased a new position in shares of Cencora in the 2nd quarter valued at $293,000. Paralel Advisors LLC purchased a new position in shares of Cencora in the 2nd quarter valued at $2,081,000. Allworth Financial LP acquired a new position in shares of Cencora during the 2nd quarter valued at $720,000. Finally, B. Metzler seel. Sohn & Co. AG acquired a new position in shares of Cencora during the 2nd quarter valued at $9,623,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

Cencora stock opened at $317.89 on Friday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The stock has a market cap of $60.66 billion, a P/E ratio of 23.62, a price-to-earnings-growth ratio of 1.81 and a beta of 0.57. The stock has a 50 day moving average of $302.59 and a 200-day moving average of $311.89.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. The business had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.00 earnings per share. On average, analysts expect that Cencora, Inc. will post 17.87 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Friday, August 14th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 14th. Cencora’s dividend payout ratio (DPR) is currently 17.83%.

Cencora announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of recent research reports. UBS Group boosted their price objective on Cencora from $412.00 to $430.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Bank of America increased their target price on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research note on Wednesday, June 24th. Evercore reiterated an “outperform” rating and set a $350.00 target price on shares of Cencora in a report on Thursday, August 6th. William Blair started coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Finally, JPMorgan Chase & Co. upped their price target on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $370.85.

Insider Buying and Selling at Cencora

In related news, Director Lauren M. Tyler bought 550 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $270.23 per share, with a total value of $148,626.50. Following the transaction, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.